Stem cells at the IPO: First blood
As a result of the IPO held on December 10 of this year, the Human Stem Cell Institute OJSC placed 15 million ordinary shares in the MICEX Innovation and Investment Market at a price of 9.5 rubles. As part of the IPO, the entire volume of shares offered to investors was placed.
The organizer of the issue is CJSC ALOR INVEST, the co–organizers of the issue are CJSC FINAM and CJSC Russian Funds.
The company is satisfied with both the organization of the IPO and its results.
As the Director General of the Human Stem Cell Institute noted: "All the tasks set by us have been completed by the company during the IPO process. The results of our work are a significant number of private investors and individuals among the IPO participants and the great interest shown by investors. This is extremely important for us and I am pleased to note this, because the work that our company's employees do is our contribution to the health of the nation and our opportunity to implement innovations for the benefit of society.
The funds received during the IPO will give an additional impetus to the development of the company and will allow it to reach the level at a faster pace. The investments received are access to new markets and the opportunity to bring unique innovative drugs to the market."
On December 11, the MICEX began secondary circulation of securities. In just two trading days, the company's securities rose by 79.8% to 17.08 rubles.
On the first day of trading on the new MICEX site, the number of transactions on shares of the Human Stem Cell Institute amounted to 6311, and the trading volume exceeded 189 million rubles.
According to Artur Isaev: "We are very excited to be the first company to open the Russian NASDAQ, an innovative platform at the MICEX. The results of the auction show the huge interest of investors in the innovative sector of the economy and their willingness to assess the prospects and potential of innovative companies. Besides, it is possible that the placement of our company is not only the beginning of the work of the Russian NASDAQ, but also an indicator of the readiness of the economy to overcome the crisis."
JSC "Institute of Human Stem Cells" is one of the leading Russian companies in the market of isolation and personal storage of human stem cells, at the same time carrying out scientific developments in the field of creation of the latest medicines based on cellular technologies.
In 2010-2011, in addition to the development of the main direction, JSC "Human Stem Cell Institute" plans to begin commercialization of a number of unique cellular preparations of its own innovative developments in the treatment of blood cancer, heart attack, ischemia, burns and skin defects. Today they are in the stage of clinical trials, which means the presence of patents and positive conclusions on laboratory studies.
Portal "Eternal youth" http://vechnayamolodost.ru according to the press service of the ISHR.
15.12.2009